Hepatitis B surface antigen reduction as a result of switching from long‐term entecavir administrati...
Hepatitis B surface antigen reduction as a result of switching from long‐term entecavir administration to tenofovir
About this item
Full title
Author / Creator
Tamaki, Nobuharu , Kurosaki, Masayuki , Kirino, Sakura , Yamashita, Koji , Osawa, Leona , Sekiguchi, Shuhei , Hayakawa, Yuka , Wang, Wan , Okada, Mao , Higuchi, Mayu , Takaura, Kenta , Maeyashiki, Chiaki , Kaneko, Shun , Yasui, Yutaka , Tsuchiya, Kaoru , Nakanishi, Hiroyuki , Itakura, Jun , Takahashi, Yuka , Enomoto, Nobuyuki and Izumi, Namiki
Publisher
Melbourne: Wiley Publishing Asia Pty Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Melbourne: Wiley Publishing Asia Pty Ltd
Subjects
More information
Scope and Contents
Contents
Background and Aim
Loss of hepatitis B surface antigen (HBsAg) is an important goal in the treatment of chronic hepatitis B. We investigated whether switching from long‐term entecavir (ETV) administration to tenofovir (TFV) (tenofovir alafenamide [TAF] or tenofovir disoproxil fumarate [TDF]) could contribute to the reduction of HBsAg levels.
...
Alternative Titles
Full title
Hepatitis B surface antigen reduction as a result of switching from long‐term entecavir administration to tenofovir
Authors, Artists and Contributors
Author / Creator
Kurosaki, Masayuki
Kirino, Sakura
Yamashita, Koji
Osawa, Leona
Sekiguchi, Shuhei
Hayakawa, Yuka
Wang, Wan
Okada, Mao
Higuchi, Mayu
Takaura, Kenta
Maeyashiki, Chiaki
Kaneko, Shun
Yasui, Yutaka
Tsuchiya, Kaoru
Nakanishi, Hiroyuki
Itakura, Jun
Takahashi, Yuka
Enomoto, Nobuyuki
Izumi, Namiki
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_07f5cac2e4b041099bd76c677205797c
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_07f5cac2e4b041099bd76c677205797c
Other Identifiers
ISSN
2397-9070
E-ISSN
2397-9070
DOI
10.1002/jgh3.12273
